SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Janux Therapeutics, Inc. (JANX) News

Follow Janux Therapeutics, Inc. (JANX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol JANX Asset equity Sector Markets 90 days 7 Last 10.09 Updated Nov 05, 2026, 10:33 PM UTC Open live news feed Open JANX chart & news
M Janux Therapeutics Reports Quarterly Results for Quarter Ended September 30 EQUITY | Nov 05, 2026, 10:33 PM UTC M Janux Therapeutics Q3 Net Loss Narrows on Lower R&D Expenses EQUITY | Nov 05, 2026, 09:44 PM UTC M Janux Therapeutics Reports Third-Quarter 2026 Financial Results Janux reported financial results for the quarter ended September 30, 2026, and provided a business update. EQUITY | Nov 05, 2026, 09:05 PM UTC M Janux Q3'26 Revenue Estimate Is 8.03M USD Janux Therapeutics is scheduled to report Q3'26 results on November 10; revenue is estimated at 8.03 million USD and EPS at (0.47) USD. The announcement time is not specified. EQUITY | Nov 03, 2026, 12:01 PM UTC L Wolfe Research upgrades JANX to Outperform, sets $23 target Wolfe Research upgrades JANX from Peerperform to Outperform and assigns a $23.00 price target, with no catalyst supplied in the alert. EQUITY | Aug 24, 2026, 11:59 AM UTC L Analysts raise ratings on ALGT, CLS, DRI, JANX and PHM A wire item says analysts upgraded ALGT to Strong Buy at Raymond James, CLS to Buy at UBS, and DRI, JANX and PHM to Outperform at Baird or Wolfe. EQUITY | Aug 24, 2026, 10:50 AM UTC L Wolfe Research upgrades JANX to Outperform, sets $23 target Wolfe Research upgrades JANX to Outperform from Peerperform and sets a $23 price target. EQUITY | Aug 24, 2026, 10:15 AM UTC M JANX: Truist Assumes Buy Truist Securities analyst assumes Janux Therapeutics with a Buy rating and lowers Price Target to $26 EQUITY | Jun 25, 2026, 02:10 PM UTC